Kefzol (Cefazolin)

Cefazolin works by binding to penicillin‑binding proteins on bacterial cell walls, inhibiting the cross‑linking of peptidoglycan strands. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death, providing a bactericidal effect against susceptible organisms.

The specific dose of Kefzol is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and route of administration. Typical regimens range from single pre‑operative doses for prophylaxis to multiple daily doses for therapeutic use, but exact dosing must follow the prescriber’s order.

Safety data for cefazolin during pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider, as cefazolin does appear in small amounts in breast milk.

To order Kefzol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will request trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with first‑generation penicillins, cefazolin offers broader coverage of Gram‑positive organisms and greater resistance to β‑lactamase degradation. Within the cephalosporin class, it provides reliable surgical prophylaxis and is often preferred over other first‑generation agents for its favorable safety profile and dosing convenience.

Kefzol should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Reconstituted solutions must be used promptly or stored according to the manufacturer’s instructions, typically refrigerated and used within a specified time frame.

Kefzol is supplied as a sterile powder for reconstitution and is administered by intravenous (IV) or intramuscular (IM) injection. The route, rate of infusion, and dilution are determined by the prescriber based on the clinical indication and patient condition.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and rare hematologic events like hemolytic anemia. Patients should be monitored for signs of these reactions, especially during the initial dosing period.

Kefzol should be avoided in individuals with a known hypersensitivity to cefazolin, other cephalosporins, or penicillins. Caution is also advised for patients with severe renal impairment, a history of severe allergic reactions, or those who have experienced severe colitis related to antibiotic therapy.